Evaluation of Amlodipine Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis

Pharmacokinetics Clinical Trial

Official title:

Evaluation of Amlodipine Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03722381
• Other study ID #: HUM00143303
• Status: Withdrawn
• Start date: January 2020
• Est. completion date: January 30, 2020

Study information

• Verified date: January 2020
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The current study will evaluate the plasma pharmacokinetics of amlodipine in a cohort of 8 adult volunteers who are receiving regular hemodialysis treatment (HD) 3 days a week for 4 hours each day and have been taking a total daily dose of 5-10 mg of amlodipine besylate for >30 days as part of their usual care. Blood sampling will occur over 13 hours, with frequent sampling during HD and in the 4 hours after termination of HD treatment. The 8 subjects will all receive their prescribed total daily dose of 5-10 mg 5 hours prior to HD treatment. The pre-HD sample will also be sent for pharmacogenomics genotyping. Safety and pharmacodynamic assessments (blood pressure (BP) and heart rate (HR) assessments) will be performed throughout the study. Axiom Precision Medicine Research Array (Affymetrix, Santa Clara, CA) will be used to evaluate genotype of CYP3A4. CYP3A4 phenotype will be evaluated using the ratio of parent drug to metabolite. Non-compartmental analyses will be performed to compare maximum concentrations (Cmax), time to maximum concentration and area under the curve from time 0 to the last measurable sample (AUClast) between the two phases. Compartmental analyses will be performed to construct a model to explain time-dependent changes in amlodipine clearance. Monte Carlo simulations will be performed to compare amlodipine pharmacokinetic profiles on and off HD.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 30, 2020
• Est. primary completion date: January 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18 years of age or older

2. Indwelling tunneled catheter, AVF, AVG that is currently used for hemodialysis

3. Receiving in-center hemodialysis 3 days a week for 3-4.5 hours each treatment

4. Taking a total daily dose of 5-10 mg of amlodipine as prescribed by their physician

5. Hemoglobin = 9.5 g/dL on most recent laboratory assessment prior to study

Exclusion Criteria:

1. Any condition that would not allow for arm BP to be taken

2. Hemoglobin < 9.5 g/dL on most recent lab prior to study

3. Patient is on a CYP3A4 inhibitor (most common in HD population include: amiodarone, clarithromycin, cyclosporine, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, nefazodone, tamoxifen, verapamil, and grapefruit juice).

Related Conditions & MeSH terms

• Hemodialysis
• Pharmacokinetics

Intervention

Drug:
• Amlodipine Besylate
Pharmacokinetics

Locations

Country	Name	City	State
United States	University of Michigan Dialysis	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Use pharmacokinetics to characterize the plasma concentration of amlodipine and its metabolite, 2-([4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl- 2-pyridyl]methoxy) acetic acid	Use pharmacokinetics to characterize the change in plasma concentration of amlodipine and its metabolite, 2-([4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl- 2-pyridyl]methoxy) acetic acid during and after HD	Pre-dialysis, during dialysis (30 minutes, 2 hours, end of treatment) and post-dialysis (30 minutes, 2 hours and 4 hours)
Secondary	Characterize the Non-renal clearance phenotype and genotype	Evaluate the non-renal clearance of amlodipine in patients on HD.	30 minutes
Secondary	Characterize the Post-dialysis Rebound	Simulate change in predicted rebound of metoprolol concentrations	post-dialysis (30 minutes, 2 hours and 4 hours)